(Q36941905)

17 August 2017

1 reference

title

Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances (English)

1 reference

17 August 2017

0 references

0 references

Paul F Smith

1

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1157-1163

1 reference

The perceived effects of smoked cannabis on patients with multiple sclerosis

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Cannabis use in HIV for pain and other medical symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Cannabinoid receptors and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Retrograde signaling by endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Cannabinoids control spasticity and tremor in a multiple sclerosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Are oral cannabinoids safe and effective in refractory neuropathic pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

The effect of cannabis on tremor in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Neuropsychological performance in long-term cannabis users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Residual neuropsychologic effects of cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Long-term effects of frequent cannabis use on working memory and attention: an fMRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Prenatal marijuana and alcohol exposure and academic achievement at age 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Effects of prenatal marijuana on response inhibition: an fMRI study of young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Tests of causal linkages between cannabis use and psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Psychotic experiences in the general population: a twenty-year prospective community study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Abstinence symptoms following oral THC administration to humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Abstinence symptoms following smoked marijuana in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

A review of the published literature into cannabis withdrawal symptoms in human users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.9.1157

10.1586/14737175.7.9.1157

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference